Suppr超能文献

相似文献

1
Control of immunity by the TNFR-related molecule OX40 (CD134).
Annu Rev Immunol. 2010;28:57-78. doi: 10.1146/annurev-immunol-030409-101243.
2
OX40, OX40L and Autoimmunity: a Comprehensive Review.
Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32. doi: 10.1007/s12016-015-8498-3.
3
4
Research progress in OX40/OX40L in allergic diseases.
Int Forum Allergy Rhinol. 2024 Dec;14(12):1921-1928. doi: 10.1002/alr.23469. Epub 2024 Oct 15.
5
OX40 and OX40L Interaction in Cancer.
Curr Med Chem. 2021;28(28):5659-5673. doi: 10.2174/0929867328666201229123151.
6
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.
Crit Rev Immunol. 2007;27(5):415-36. doi: 10.1615/critrevimmunol.v27.i5.20.
7
Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.
Front Immunol. 2025 Jan 10;15:1473815. doi: 10.3389/fimmu.2024.1473815. eCollection 2024.
8
OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.
Adv Immunol. 2010;105:63-98. doi: 10.1016/S0065-2776(10)05003-0.
9
OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.
JCI Insight. 2018 Dec 20;3(24):122167. doi: 10.1172/jci.insight.122167.
10
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15.

引用本文的文献

1
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.
Dermatol Ther (Heidelb). 2025 Sep 6. doi: 10.1007/s13555-025-01492-1.
2
Promising Molecular Therapeutic Targets for Drug Development in Rheumatoid Arthritis.
J Clin Med. 2025 Aug 18;14(16):5827. doi: 10.3390/jcm14165827.
4
CD4 T cells promote fibrosis during metabolic dysfunction-associated steatohepatitis.
bioRxiv. 2025 Jul 3:2025.06.27.660220. doi: 10.1101/2025.06.27.660220.
6
Anti-OX40 antibody BAT6026 in patients with advanced solid tumors: A multi-center phase I study.
iScience. 2025 Mar 22;28(6):112270. doi: 10.1016/j.isci.2025.112270. eCollection 2025 Jun 20.
8
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.
J Immunother Cancer. 2025 May 21;13(5):e011524. doi: 10.1136/jitc-2025-011524.
9
Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.
MedComm (2020). 2025 Apr 21;6(5):e70182. doi: 10.1002/mco2.70182. eCollection 2025 May.

本文引用的文献

2
The role of TNF superfamily members in T-cell function and diseases.
Nat Rev Immunol. 2009 Apr;9(4):271-85. doi: 10.1038/nri2526.
3
NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner.
Immunity. 2009 Feb 20;30(2):289-99. doi: 10.1016/j.immuni.2008.12.017. Epub 2009 Feb 12.
5
OX40 drives protective vaccinia virus-specific CD8 T cells.
J Immunol. 2008 Dec 1;181(11):7969-76. doi: 10.4049/jimmunol.181.11.7969.
6
OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells.
J Immunol. 2008 Nov 1;181(9):5990-6001. doi: 10.4049/jimmunol.181.9.5990.
8
The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome.
Clin Chim Acta. 2008 Nov;397(1-2):22-6. doi: 10.1016/j.cca.2008.07.003. Epub 2008 Jul 12.
10
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.
Chem Biol. 2008 Jul 21;15(7):675-82. doi: 10.1016/j.chembiol.2008.05.016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验